These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27826123)

  • 1. Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia.
    Lemoli RM; Parisi S; Curti A
    Exp Hematol; 2017 Jan; 45():10-16. PubMed ID: 27826123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant.
    Yeral M; Kasar M; Boga C; Kozanoglu I; Ozdogu H; Sariturk C
    Exp Clin Transplant; 2015 Oct; 13(5):453-60. PubMed ID: 26103468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cell therapy for acute myeloid leukemia.
    Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
    Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future.
    Muntasell A; López-Botet M
    Clin Cancer Res; 2016 Apr; 22(8):1831-3. PubMed ID: 26903071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in acute myeloid leukemia.
    Arpinati M; Curti A
    Immunotherapy; 2014; 6(1):95-106. PubMed ID: 24341888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with natural killer cells: a possible approach for the treatment of Acute Myeloid Leukemia also in Brazil.
    Silla L
    Rev Assoc Med Bras (1992); 2016 Oct; 62 Suppl 1():23-24. PubMed ID: 27982314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.
    Limongello R; Marra A; Mancusi A; Bonato S; Hoxha E; Ruggeri L; Hui S; Velardi A; Pierini A
    Front Immunol; 2021; 12():695051. PubMed ID: 34413848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
    Parisi S; Ruggeri L; Dan E; Rizzi S; Sinigaglia B; Ocadlikova D; Bontadini A; Giudice V; Urbani E; Ciardelli S; Sartor C; Cristiano G; Nanni J; Zannoni L; Chirumbolo G; Arpinati M; Lewis RE; Bonifazi F; Marconi G; Martinelli G; Papayannidis C; Paolini S; Velardi A; Cavo M; Lemoli RM; Curti A
    Front Immunol; 2021; 12():804988. PubMed ID: 35173709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell-based immunotherapy for acute myeloid leukemia.
    Xu J; Niu T
    J Hematol Oncol; 2020 Dec; 13(1):167. PubMed ID: 33287858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
    Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
    Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
    Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
    Boyiadzis M; Agha M; Redner RL; Sehgal A; Im A; Hou JZ; Farah R; Dorritie KA; Raptis A; Lim SH; Wang H; Lapteva N; Mei Z; Butterfield LH; Rooney CM; Whiteside TL
    Cytotherapy; 2017 Oct; 19(10):1225-1232. PubMed ID: 28864289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches for the immunotherapy of acute myeloid leukemia.
    Geiger TL; Rubnitz JE
    Discov Med; 2015 Apr; 19(105):275-84. PubMed ID: 25977190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Lulla PD; Mamonkin M; Brenner MK
    Cancer J; 2019; 25(3):199-207. PubMed ID: 31135527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment.
    Krakow EF; Bergeron J; Lachance S; Roy DC; Delisle JS
    Blood Rev; 2014 Nov; 28(6):249-61. PubMed ID: 25228333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells.
    Lee DA
    Immunol Rev; 2019 Jul; 290(1):85-99. PubMed ID: 31355489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
    Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
    Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cellular immunotherapy in chronic myeloid leukemia].
    Fernández MN
    Sangre (Barc); 1998 Apr; 43(2):164-70. PubMed ID: 9656778
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
    Guo H; Qian X
    Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.
    Cooley S; He F; Bachanova V; Vercellotti GM; DeFor TE; Curtsinger JM; Robertson P; Grzywacz B; Conlon KC; Waldmann TA; McKenna DH; Blazar BR; Weisdorf DJ; Miller JS
    Blood Adv; 2019 Jul; 3(13):1970-1980. PubMed ID: 31266741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.